How to Value a Veterinary Dermatology Practice in 2026

Veterinary dermatology is one of the most interesting niches I encounter in practice transactions. The economics are driven by a simple supply-demand imbalance: there are approximately 300 board-certified veterinary dermatologists (DACVDs) in the entire United States, and the number of pets with chronic skin conditions, allergies, and autoimmune diseases is growing faster than the specialty can produce new diplomates. That scarcity creates valuations that most general veterinary specialty practices can't match.

Here's how veterinary dermatology practices are valued in 2026, and what makes this niche unlike anything else in veterinary M&A.

The Premium Multiple: 5-10x EBITDA

Veterinary dermatology practices trade at 5-10x EBITDA, which puts them at the very top of the veterinary valuation spectrum. For context, general veterinary practices typically sell at 5-8x EBITDA, and most veterinary specialties land at 6-9x. Dermatology consistently commands a premium, and the reasons are structural.

The DACVD credential takes a minimum of 3 years of residency training after veterinary school, passage of a comprehensive board examination, and published research. The failure rate on the board exam is significant. The total pipeline from entering vet school to becoming a board-certified dermatologist is 11-12 years. You cannot accelerate this. You cannot shortcut it. And there are fewer than 40 new DACVDs produced each year.

That means when a corporate consolidator or private equity group wants to add veterinary dermatology to their platform, they essentially must acquire an existing practice. They can't build one from scratch without a DACVD, and recruiting a DACVD away from an established practice is extremely difficult and expensive. This acquisition-or-nothing dynamic pushes multiples to the top of the range.

The Recurring Revenue Engine: Allergy Testing and Immunotherapy

What makes veterinary dermatology particularly attractive to financially sophisticated buyers is the recurring revenue component. Unlike orthopedic surgery (one-time procedure) or emergency medicine (episodic), dermatology generates ongoing patient relationships that can last 8-12 years — the lifetime of the pet.

The economics work like this: a dog presents with chronic pruritus (itching). Initial workup includes skin cytology, culture, and intradermal allergy testing ($400-800 for the testing alone). If allergies are confirmed — and they usually are — the patient begins allergen-specific immunotherapy. The immunotherapy protocol involves custom-formulated allergy serum ($250-400 every 3-6 months), monitoring appointments ($150-250 every 3-4 months), and periodic retesting.

A single allergy patient generates $1,200-2,500 in annual recurring revenue. A mature dermatology practice might have 400-800 active immunotherapy patients. That's $500K-2M in high-margin recurring revenue that renews automatically because stopping immunotherapy means the pet's symptoms return. Owners don't cancel; they refill.

Buyers who understand recurring revenue — and PE buyers absolutely do — will pay 8-10x for a practice with a large, well-documented immunotherapy patient base. The predictability of that revenue stream is worth a significant premium over a practice that's primarily doing one-time consultations.

Referral Dynamics and What They Mean for Value

Veterinary dermatology is almost entirely referral-based. General practitioners and emergency vets refer cases they can't resolve — chronic ear infections that don't respond to standard treatment, suspected autoimmune skin diseases, complex allergy cases, and unusual dermatologic presentations. Your referral network is your patient acquisition engine.

The valuation question is how concentrated and how durable those referral relationships are. A practice receiving referrals from 80+ general practices across a metro area has a fundamentally different risk profile than one getting 60% of referrals from three large multi-doctor clinics.

Buyers evaluate referral durability through several lenses:

• Geographic coverage: Are you the only DACVD within a 60-90 minute drive? In many markets, the answer is yes, which makes your referral relationships sticky by default — there's simply no alternative for referring vets to send their cases to.
• Referral communication: Do you send detailed reports back to referring veterinarians? Do you maintain the referring vet's primary relationship with the client? Practices that communicate well retain referral sources through ownership transitions.
• Wait times: Paradoxically, moderate wait times (3-6 weeks for non-urgent cases) signal demand strength. If you're seeing patients the same week, a buyer might worry about referral volume. If the wait is 3+ months, you may be turning away cases.

What Drives the Multiple Higher

Multiple DACVDs on staff. A practice with two or three board-certified dermatologists is exponentially more valuable than a solo practitioner, not just because of the revenue, but because the clinical capability survives if one dermatologist leaves. Solo DACVD practices trade at 5-7x; multi-DACVD practices command 8-10x.

Large immunotherapy patient base. The number of active immunotherapy patients is arguably the single most important metric in veterinary dermatology valuation. Each patient represents a quantifiable stream of future revenue. Practices with 500+ active immunotherapy patients and documented refill compliance rates above 80% attract the strongest offers.

Apoquel/Cytopoint management alongside immunotherapy.The introduction of Apoquel and Cytopoint has changed the dermatology revenue mix. Smart practices use these as bridge therapy while building immunotherapy programs and as long-term management for patients where immunotherapy alone isn't sufficient. This creates a pharmaceutical revenue layer on top of the service revenue.

Clinical trials and research partnerships. Practices that participate in pharmaceutical clinical trials for new dermatologic products generate additional revenue ($50-150K annually for active trial sites) and signal clinical sophistication that corporate buyers value.

What Suppresses Value

Solo DACVD who is also the owner.This is the central tension in veterinary dermatology M&A. The DACVD is both the most valuable asset and the biggest risk factor. If the board-certified dermatologist leaves, the practice can't function as a dermatology referral center. Buyers mitigate this with employment agreements (typically 3-5 year commitments post-acquisition), but the risk still compresses the multiple for solo-DACVD practices.

Facility limitations. Dermatology practices need specific infrastructure: video otoscopy, dermatoscopy, a properly equipped lab for cytology and culture, and ideally space for intradermal testing. Practices operating out of cramped subleased space within a general practice face facility risk that buyers will price in.

Poor immunotherapy compliance tracking.If you can't tell a buyer what percentage of your allergy patients are compliant with their immunotherapy refills, you're leaving money on the table — both in current revenue (unworked refill reminders) and in valuation (unproven recurring revenue claims). Implement systematic refill tracking and compliance outreach.

Over-reliance on one referral source. If a single veterinary hospital group sends you 40%+ of your cases and that group gets acquired by a corporate entity with their own dermatology referral preferences, your patient pipeline could collapse. Diversification across referral sources is essential.

The Buyer Landscape

Three buyer categories dominate veterinary dermatology acquisitions in 2026.

Veterinary specialty consolidators— groups like Ethos Veterinary Health, BluePearl (Mars), and NVA's specialty division — are the most active and highest-paying buyers. They're building multi-specialty referral platforms and dermatology is a high-priority addition because of its recurring revenue profile. These buyers pay 7-10x EBITDA for well-positioned practices.

General veterinary consolidators adding specialty services to their networks. Companies like VCA and National Veterinary Associates acquire dermatology practices to offer specialty referrals within their existing hospital networks. They pay 6-8x but may offer strategic value through guaranteed referral volume from their general practice portfolio.

Individual DACVDs looking to own rather than be employed. These buyers are less common (most DACVDs prefer clinical work to business ownership) but when they appear, they understand the clinical value deeply. They typically pay 5-7x and finance through SBA or conventional veterinary practice loans.

The Bottom Line

Veterinary dermatology sits at the intersection of supply scarcity, recurring revenue, and consolidation demand — three factors that independently drive premium valuations and together create some of the highest multiples in veterinary M&A. The difference between 5x and 10x comes down to whether you've built an institution or a personal practice. Multiple DACVDs, a large immunotherapy patient base with documented compliance, diversified referral sources, and proper facility infrastructure are what separate the good outcomes from the exceptional ones. If you're a DACVD thinking about your exit in the next 3-5 years, the investment in building these elements will be the most financially rewarding decision of your career.